PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest-Reference-Cited by-同舟云学术

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

Published:2019-12-14 Issue:4 Volume:47 Page:895-906
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Bodei Lisa^ORCID,Kidd Mark S.,Singh Aviral,van der Zwan Wouter A.,Severi Stefano,Drozdov Ignat A.,Malczewska Anna,Baum Richard P.,Kwekkeboom Dik J.,Paganelli Giovanni,Krenning Eric P.,Modlin Irvin M.

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-019-04601-3.pdf

Reference31 articles.

1. Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):179–91. https://doi.org/10.1016/j.hoc.2015.09.009.

2. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.

3. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.

4. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.

5. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer. 2017;24(5):243–51. https://doi.org/10.1530/ERC-16-0524.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice;JCO Precision Oncology;2024-09

2. The Clinical Utility of the NETest in Patients with Small Intestinal Neuroendocrine Neoplasms (Si-NENs): A “Real-Life” Study;Cancers;2024-07-10

3. NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms;Journal of Neuroendocrinology;2024-06-27

4. Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review;Diagnostics;2024-06-18

5. Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors;Frontiers in Endocrinology;2024-06-14